Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn's Disease: Experience from the METRIC Trial.
Kumar S, Parry T, Mallett S, Bhatnagar G, Plumb A, Walsh S, Scott N, Tandon R, Chong H, du Parcq J, Martinez A, Moorghen M, Rodriguez-Justo M, Halligan S, Taylor SA; METRIC study investigators. Kumar S, et al. J Crohns Colitis. 2022 Nov 1;16(10):1531-1539. doi: 10.1093/ecco-jcc/jjac062. J Crohns Colitis. 2022. PMID: 35481898 Free PMC article.
METRIC-EF: magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn's disease-protocol for a multicentre, non-randomised, single-arm, prospective study.
Kumar S, Plumb A, Mallett S, Bhatnagar G, Bloom S, Clarke CS, Hamlin J, Hart AL, Jacobs I, Travis S, Vega R, Halligan S, Taylor SA. Kumar S, et al. Among authors: vega r. BMJ Open. 2022 Oct 3;12(10):e067265. doi: 10.1136/bmjopen-2022-067265. BMJ Open. 2022. PMID: 36192092 Free PMC article.
Lipidomic profiling in Crohn's disease: abnormalities in phosphatidylinositols, with preservation of ceramide, phosphatidylcholine and phosphatidylserine composition.
Sewell GW, Hannun YA, Han X, Koster G, Bielawski J, Goss V, Smith PJ, Rahman FZ, Vega R, Bloom SL, Walker AP, Postle AD, Segal AW. Sewell GW, et al. Among authors: vega r. Int J Biochem Cell Biol. 2012 Nov;44(11):1839-46. doi: 10.1016/j.biocel.2012.06.016. Epub 2012 Jun 19. Int J Biochem Cell Biol. 2012. PMID: 22728312 Free PMC article.
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.
Miller C, Kwok H, Harrow P, Vega R, Seward E, Mehta S, Rahman F, McCartney S, Parisi I, Lim SH, Sharma E, Samaan MA, Bancil A, Kok KB, Shalabi A, Johnston EL, Katarey D, Taherzadeh N, Murray C, Sharip MT, Carter MJ, Radhakrishnan ST, Peake S, Khakoo I, Wahed M, Povlsen S, Patel M, DuBois P, Finkel J, Onnie C, Bloom S. Miller C, et al. Among authors: vega r. Frontline Gastroenterol. 2022 Jan 7;13(5):392-401. doi: 10.1136/flgastro-2021-101906. eCollection 2022. Frontline Gastroenterol. 2022. PMID: 36051959 Free PMC article.
Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.
Inniss S, Fragkos KC, Whitley L, Wimpory R, Rebello E, Lisboa A, Khetan T, Hassan J, Simpson K, Bhagwanani A, Vega R, Parisi I, Harrow P, Seward E, McCartney S, Bloom S, Smith AM, Plumb A, Rahman FZ. Inniss S, et al. Among authors: vega r. Ther Adv Chronic Dis. 2023 Aug 16;14:20406223231189072. doi: 10.1177/20406223231189072. eCollection 2023. Ther Adv Chronic Dis. 2023. PMID: 37601038 Free PMC article.
684 results